Harmony Alliance Provides a Machine Learning Researching Tool to Predict the Risk of Relapse after First Remission in AML Patients Treated without Allogeneic Haematopoietic Stem Cell TransplantationMarta Sobas, Jesús María Hernández‐Rivas, Castellani Gastone et al.|Blood|2021Cited by 4
Does RAD21 Co-Mutation Have a Role in DNMT3A Mutated AML? Results of Harmony Alliance AML DatabaseRaúl Azibeiro Melchor, Gert J. Ossenkoppele, Alberto Hernández‐Sánchez et al.|Blood|2021Cited by 1
Impact of Gender on Molecular AML Subclasses - a Harmony Alliance StudyTommaso Matteuzzi, Lars Bullinger, Daniele Dall’Olio et al.|Blood|2021Cited by 1
Long-Term Follow-up of AML Patients Treated Intensively before the Era of Targeted Agents. a Big Data Analysis from the Harmony CollaborationMarta Sobas, Lars Bullinger, Ángela Villaverde Ramiro et al.|Blood|2022Cited by 1